INTS Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 140803 min ago

@ $3.41

Wydano: 12 vas. 2024 @ 21:19

Zwrot: 42.04%

Poprzedni sygnał: vas. 8 - 19:41

Poprzedni sygnał: Sprzedaż

Zwrot: -5.28 %

Live Chart Being Loaded With Signals

Commentary (20 geg. 2024 @ 16:56):

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors...

Stats
Dzisiejszy wolumen	1 108.00
Średni wolumen	37 575.00
Kapitalizacja rynkowa	66.41M
EPS	$0 ( 2024-04-01 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.51
ATR14	$0.0410 (0.85%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-14	Dubin Thomas I H	Buy	50 000	Stock Option (right to buy Common Stock)
2024-05-14	Dubin Thomas I H	Buy	0
2024-03-06	Wesolowski John M	Buy	25 000	Stock Option (right to buy Common Stock)
2024-03-06	Leahy Emer	Buy	50 000	Stock Option (right to buy Common Stock)
2024-03-06	Goldberg Mark A	Buy	50 000	Stock Option (right to buy Common Stock)

INSIDER POWER
59.93
Last 24 transactions
Buy: 853 379 \| Sell: 331 500

Wolumen Korelacja

Długi: -0.27 (neutral)

Krótki: -0.80 (moderate negative)

Signal:(43.754) Neutral

Intensity Therapeutics, Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Intensity Therapeutics, Korelacja - Waluta/Towar

0.20
( neutral )

0.30
( neutral )

0.00
( neutral )

0.40
( neutral )

-0.61
( weak negative )

-0.50
( neutral )

Intensity Therapeutics, Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-147 000 (0.00 %)
EPS:	$-1.220

FY	2023
Przychody:	$0
Zysk brutto:	$-147 000 (0.00 %)
EPS:	$-1.220

FY	2022
Przychody:	$0
Zysk brutto:	$-179 037 (0.00 %)
EPS:	$-0.570

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.439

Financial Reports:

No articles found.

Intensity Therapeutics, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Intensity Therapeutics,

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.